SURVYR

VKTX

Viking Therapeutics, Inc.
$24.21
−$0.19 (0.78%)Oct 26 close
Biotech & HealthcareSP500 CompareTechnicals
1M3M6M1Y2Y
-33%-19%-6%+7%+20%Oct 2025Oct 2026Apr 202652w high $43.1552w low $24.36
VKTXSPY
Wall St. Highest PT $125.00 (+416.3%) Wall St. Avg PT $95.05 (+292.6%)
$24$61$97$134$170POC $34Hi $125Avg $95
Underwater Drawdown %Max DD -42.5%Current -42.5%
0.0%-42.5%
Relative Strength vs SPY-45.5% vs SPYUnderperforming
+52%0%-52%
1W
−$0.84 (3.35%)
1M
−$11.35 (31.92%)
3M
−$10.66 (30.57%)
6M
−$8.78 (26.60%)
YTD
−$10.97 (31.18%)
1Y
−$10.21 (29.66%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
19 analysts · mean score 1.43
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$24.21
Average target$95.05
+$70.84 (+292.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$38.00
Median$95.05
High$125.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-20 · Canaccord Genuity reiterated Buy on VKTX
Initiated
2026-10-15 · UBS started covering VKTX at Buy
Reiterated
2026-10-07 · Truist Securities reiterated Buy on VKTX
Reiterated
2026-09-23 · Truist Securities reiterated Buy on VKTX
Reiterated
2026-08-11 · JP Morgan reiterated Overweight on VKTX
Reiterated
2026-07-30 · Canaccord Genuity reiterated Buy on VKTX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.1B
P/E (next 12 months, estimated)-5.6
52-week range$24.36 – $43.15
Dividend yieldNo dividend
Analyst consensusStrong Buy (19)
Average analyst price target$95.05 (+293%)

What they do

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for VKTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: SURVYR. Barbell Momentum & T-Bill Shield.

SURVYR. Barbell Momentum & T-Bill Shield
5.0% of the book · Mid-Cap RS & EPS Leaders (75%) sleeve · ranked 7 of 160
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the SURVYR. Barbell Momentum & T-Bill Shield #7 of 160

Qualified on Phase 3 VANQUISH obesity readout catalyst + clean cash runway. Ranked 7th of 160 at the 2026-10-01 rebalance.

What would knock it out: Drops out if it falls outside the top 16 at the next rebalance (Oct 30).

Earnings & events

VKTX earningsReports tomorrow
Next report · quarter Sep 2026
Wed Oct 28, 2026After the close
EPS consensus-$1.06 range -$1.38–-$0.66
Revenue consensus$0 17 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026-$1.10est -$1.21+8.8%Above estimates
Apr 29, 2026-$1.37est -$0.91−50.5%Below estimates
Feb 11, 2026-$1.38est -$0.90−53.1%Below estimates
Oct 22, 2025-$0.81est -$0.67−20.1%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-23 23:32:35 ET
24-1025-0225-0425-0725-1026-0226-0426-07-1.380.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Zacks · Oct 06

Research

Coteau Barbell Momentum & T-Bill Shield: rebalance of Oct 1, 2026Oct 26, 2026
Rating changes
Reiterated
2026-10-20 · Canaccord Genuity reiterated Buy on VKTX
Initiated
2026-10-15 · UBS started covering VKTX at Buy
Reiterated
2026-10-07 · Truist Securities reiterated Buy on VKTX
Reiterated
2026-09-23 · Truist Securities reiterated Buy on VKTX
Reiterated
2026-08-11 · JP Morgan reiterated Overweight on VKTX
Reiterated
2026-07-30 · Canaccord Genuity reiterated Buy on VKTX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Mancini Marianna
Chief Operating Officer · 2026-07-29
Sell
$609.6K
Zante Greg
Chief Financial Officer · 2026-07-29
Sell
$710.1K
Lian Brian
Director, President & CEO · 2026-07-29
Sell
$4.9M
None
None · None
Sell
–

Stats refreshed 2026-10-23 23:32:35 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026